The groundbreaking rise of Viagra has consistently remained a symbol of pharmaceutical success, but its legacy within the broader market now raises questions about long-term yields . Copycat versions are eroding patent protection , prompting concerns that investing in companies closely tied to Viagra's former standing could be a problematic decisio